Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N GRAFF

Showing results (61-70 of 104) with videos related to

Pageof 11
Sort By:
Frontiers in Oncology|August 28, 2020
Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation TherapyJulie N Graff, Mark N Stein, Rishi Surana, et al.
Journal of Surgical Education|October 21, 2015
A Disease-Specific Hybrid Rotation Increases Opportunities for Deliberate PracticeMackenzie R Cook, Amanda N Graff-Baker, Alexis M Moren, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineagesYa-Mei Hu, Faming Zhao, Julie N Graff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILJ N Graff, G Baciarello, A J Armstrong, et al.
Oncotarget|July 19, 2016
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancerJulie N Graff, Joshi J Alumkal, Charles G Drake, et al.
Neurology|July 11, 2007
A plateau in pre-Alzheimer memory decline: evidence for compensatory mechanisms?G E Smith, V S Pankratz, S Negash, et al.
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancerC N Sternberg, F Saad, J N Graff, et al.
Oncotarget|October 27, 2017
Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancerJennifer Podolak, Kristi Eilers, Timothy Newby, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
Pageof 11

Showing results (61-70 of 104) with videos related to

Sort By:
Pageof 11
Frontiers in Oncology|August 28, 2020
Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation TherapyJulie N Graff, Mark N Stein, Rishi Surana, et al.
Journal of Surgical Education|October 21, 2015
A Disease-Specific Hybrid Rotation Increases Opportunities for Deliberate PracticeMackenzie R Cook, Amanda N Graff-Baker, Alexis M Moren, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineagesYa-Mei Hu, Faming Zhao, Julie N Graff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2015
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILJ N Graff, G Baciarello, A J Armstrong, et al.
Oncotarget|July 19, 2016
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancerJulie N Graff, Joshi J Alumkal, Charles G Drake, et al.
Neurology|July 11, 2007
A plateau in pre-Alzheimer memory decline: evidence for compensatory mechanisms?G E Smith, V S Pankratz, S Negash, et al.
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancerC N Sternberg, F Saad, J N Graff, et al.
Oncotarget|October 27, 2017
Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancerJennifer Podolak, Kristi Eilers, Timothy Newby, et al.
European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.
Pageof 11